Tue07052022

Last updateFri, 01 Jul 2022 11pm

Back You are here: Inicio Biology & biomedicine Projects

Heart therapies: scientists have succesfully designed and tested beta blockers controlled by light

A research tested in zebrafish shows the potential of photopharmacology for future heart therapies more precise and with fewer side effects. The study is published in the journal Angewandte Chemie International Edition, selected as a Hot Paper.

Read more ...

A new targeted nanosystem improves brain drug delivery for the treatment after a stroke

Direct brain administration through the carotid artery of nanomaterials carrying drugs after a stroke could be an effective method to reduce the undesirable effects in other organs, improving at the same time the arrival of the drug into the brain. A study has tested nanocapsules designed by scientists at the ICMAB-CSIC to transport drug molecules to brain areas by a micro catheter.

Read more ...

SINGEK trains a new generation of Single Cell Genomics experts

The SINGEK project is now finished. It was a project coordinated by the Institut de Ciències del Mar (ICM, by its Spanish acronym) of the CSIC, and it had as a main goal the training of young researchers in the application of single cell genomics for the study of microbial eukaryotes’ ecology and evolution. This emerging methodology also has applications in biotechnology and biomedicine.

Read more ...

A molecular mechanism of the cardiac alternans, one of the causes of severe cardiac arrhythmia, has been identified

An international project with participation of IIBB-CSIC has identified one of the molecular mechanisms that causes the so-called “cardiac alternans”, an alteration of the cardiac rhythm that can cause ventricular fibrillation and potentially lethal cardiac arrhythmia. This finding opens a new path to the development of pharmacological treatment.

Read more ...

A new therapeutic target for the treatment of nonalcoholic fatty liver disease

Scientists of the IIBB-CSIC discover a new role for sphingomyelin synthase 1 enzyme in nonalcoholic steatohepatitis, an advanced stage of fatty liver disease. The work identifies SMS1 enzyme as a possible new therapeutic target.

Read more ...